ETV2/ER71 Transcription Factor as a Therapeutic Vehicle for Cardiovascular Disease

• Authors: Dong Hun Lee, Emory University; Tae Min Kim, Seoul National University; Joo Kyung Kim, Emory University; Changwon Park, Emory University
• Journal Title: Theranostics
• Volume: Volume 9, Number 19
• Publisher: Ivyspring International Publisher | 2019-01-01, Pages 5694-5705
• Type of Work: Article | Final Publisher PDF
• Publisher DOI: http://doi.org/10.7150/thno.35300
• Subjects: Chemistry, Biochemistry; Health Sciences, Pharmacology
• Keywords: Science & Technology; Life Sciences & Biomedicine; Medicine, Research & Experimental; Research & Experimental Medicine; ER71/ETV2; FLK1/VEGFR2; cardiovascular; angiogenesis; direct cell reprogramming; CARDIAC LYMPHATIC OBSTRUCTION; ADULT HUMAN FIBROBLASTS; ENDOTHELIAL-CELLS; GENE-TRANSFER; EXTRACELLULAR VESICLES; VASCULAR REGENERATION; MYOCARDIAL-INFARCTION; FUNCTIONAL-NEURONS; DIRECT CONVERSION; MASTER REGULATOR

Abstract

Cardiovascular diseases have long been the leading cause of mortality and morbidity in the United States as well as worldwide. Despite numerous efforts over the past few decades, the number of the patients with cardiovascular disease still remains high, thereby necessitating the development of novel therapeutic strategies equipped with a better understanding of the biology of the cardiovascular system. Recently, the ETS transcription factor, ETV2 (also known as ER71), has been recognized as a master regulator of the development of the cardiovascular system and plays an important role in pathophysiological angiogenesis and the endothelial cell reprogramming. Here, we discuss the detailed mechanisms underlying ETV2/ER71-regulated cardiovascular lineage development. In addition, recent reports on the novel functions of ETV2/ER71 in neovascularization and direct cell reprogramming are discussed with a focus on its therapeutic potential for cardiovascular diseases.